• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Emergency

Combined use of cannabis and alcohol may increase driving impairment and subjective intoxication

bySiwen LiuandSimon Pan
May 8, 2026
in Emergency, Pharma
Reading Time: 2 mins read
Systematic review examines benefits and adverse effects of cannabinoid therapy
Share on FacebookShare on Twitter

1. Co-use of cannabis edibles and alcohol augmented driving impairment and subjective intoxication.

Evidence Rating Level: 2 (Good)

Previous research has found that the co-use of cannabis and alcohol impairs driving ability and cognitive and behavioral performance to a greater extent than when used individually. While previous studies focused on inhaled forms of cannabis and alcohol, there is a lack of research on the co-use of cannabis edibles and alcohol. This study thus examined the individual and interactive effects of cannabis edibles and alcohol on simulated driving, as well as subjective and objective impairment measures. This crossover study included healthy adults aged 21-55 who underwent 7 outpatient experimental sessions at Johns Hopkins University School of Medicine from February 2022 to August 2025. During the sessions, participants consumed a cannabis-infused brownie (10 mg or 25 mg THC) or a placebo brownie, followed by an alcohol-containing drink adjusted to reach breath alcohol concentrations (BrAC) of 0.05% or 0.08% or a placebo drink. The primary driving outcome was the global drive score (GDS). Field sobriety was assessed using the Standardized Field Sobriety Tests (SFST). Subjective drug effects were assessed with the various questionnaires. In total, 25 participants were included in the study (mean [SD] age, 25.6 [4.9] years, 15 males [60%]). Based on mean peak GDS, all active drug conditions except 10 mg THC reduced driving performance compared with placebo. Compared to consuming alcohol alone at 0.08% BrAC, driving impairment was similar at 0.05% BrAC and 10 mg THC (mean [SD] peak GDS, 1.6 [1.6] vs 1.6 [1.4]) but worse at 0.05% BrAC and 25 mg THC (mean [SD] peak GDS, 2.5 [1.7]; P = .02). Driving impairment and subjective intoxication were often greater under co-use conditions compared with cannabis or alcohol alone. Compared to placebo, SFST performance worsened at 0.08% BrAC (mean [SD] score, 2.2 [2.2] vs 0.2 [1.3]; P = .008). Overall, this study found that co-use of cannabis edibles and alcohol augmented driving impairment and subjective intoxication. These findings suggest that the legal alcohol intoxication limit of 0.08% BrAC in most of the US may be too liberal if a driver has also used cannabis. 

Click here to read this study in JAMA Network Open

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Alcohol use declines but remains above pre-pandemic levels

Limited pharmacotherapy initiation during veteran hospitalizations for alcohol use disorder

2 Minute Medicine Rewind May 4, 2026

Tags: alcohol usecannabisdriving under the influence (DUI)intoxication
Previous Post

Orforglipron (Foundayo) expands oral treatment options for weight management

Next Post

2 Minute Medicine Rewind May 11, 2026

RelatedReports

Psychiatry

Alcohol use declines but remains above pre-pandemic levels

September 22, 2026
Increased risk of stillbirth recurrence after a previous stillbirth
Chronic Disease

Limited pharmacotherapy initiation during veteran hospitalizations for alcohol use disorder

May 4, 2026
Systematic review examines benefits and adverse effects of cannabinoid therapy
Weekly Rewinds

2 Minute Medicine Rewind May 4, 2026

May 4, 2026
Systematic review examines benefits and adverse effects of cannabinoid therapy
Chronic Disease

Baseline cannabis use may not be associated with abstinence from vaping

January 13, 2026
Next Post
Live attenuated vaccine less effective in recent influenza season

2 Minute Medicine Rewind May 11, 2026

Collage of medical tech icons circling a central chip with 'AI Roundup' title and 2 Minute Medicine logo in teal background.

2MM: AI Roundup – PrescriberPoint launches autonomous agent for prior authorization, Utah begins first in nation autonomous AI prescribing pilot, and JAMA study confirms ambient AI scribes return hours to the clinician work week

Combined immunotherapy may improve survival in metastatic pancreatic cancer

Activated factor VIII-mimetic prophylaxis associated with reduced bleeding in hemophilia A

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence (AI) capable of identifying uncommon gastrointestinal pathologies despite no targeted disease training
  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.